A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

Published:2018-05-08 Issue:2 Volume:182 Page:222-230
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

O'Donnell Elizabeth K.¹²^ORCID,Laubach Jacob P.²³,Yee Andrew J.¹²⁴,Chen Tianqi³,Huff Carol Ann⁵,Basile Frank G.⁶,Wade Philip M.⁶,Paba-Prada Claudia E.²³,Ghobrial Irene M.²³,Schlossman Robert L.²³,Burke Jill N.¹,Harrington Cynthia C.¹,Lively Kathleen J.¹,Lyons Hannah F.⁴,Munshi Nikhil C.²³,Anderson Kenneth C.²³,Trippa Lorenzo³,Richardson Paul G.²³^ORCID,Raje Noopur S.¹²

Affiliation:

1. Massachusetts General Hospital Cancer Center; Boston MA USA

2. Harvard Medical School; Boston MA USA

3. Dana-Farber Cancer Institute; Boston MA USA

4. Mass General/North Shore Cancer Center; Danvers MA USA

5. Johns Hopkins Hospital; Baltimore MD USA

6. Cape Cod Hospital; Hyannis MA USA

Funder

Takeda Pharmaceuticals U.S.A.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15261/fullpdf

Reference27 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology;Aaronson;Journal of the National Cancer Institute,1993

2. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma;Benboubker;New England Journal of Medicine,2014

3. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma;Cocks;European Journal of Cancer,2007

4. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide;Delforge;Haematologica,2015

5. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma;Dimopoulos;Leukemia,2009

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma;American Journal of Hematology;2024-09-10

2. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial;Nature Medicine;2024-06-03

3. The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry;Clinical Lymphoma Myeloma and Leukemia;2024-06

4. Personalized Treatment of Multiple Myeloma in Frail Patients;Current Oncology Reports;2024-05-18

5. Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database;eJHaem;2024-04-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3